09:43:21 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandFinland
ListaSmall Cap Helsinki
SektorHälsovård
IndustriMedicinteknik
Optomed är verksamma inom medicinteknik. Bolaget bedriver forskning och utveckling av specialiserade ögonkameror. Utveckling sker av både hård- och mjukvara som vidaresäljs under olika varumärken. Verksamhet innehas på global nivå, med störst närvaro inom den nordiska marknaden. Kunderna består av forskningsinstitut samt sjukhus. Huvudkontoret ligger i Oulu.

Kalender

2022-11-03 Kvartalsrapport 2022-Q3
2022-08-04 Kvartalsrapport 2022-Q2
2022-05-10 Årsstämma 2022
2022-05-05 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-04 Kvartalsrapport 2021-Q3
2021-08-05 Kvartalsrapport 2021-Q2
2021-05-06 Kvartalsrapport 2021-Q1
2021-04-29 Ordinarie utdelning OPTOMED 0.00 EUR
2021-04-28 Årsstämma 2021
2021-02-18 Bokslutskommuniké 2020
2020-11-25 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-06-12 Ordinarie utdelning OPTOMED 0.00 EUR
2020-06-11 Årsstämma 2020
2020-05-29 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2021-05-26 12:30:00

Optomed Plc         Stock Exchange Release    26 May 2021 at 13.30, Helsinki

Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings

Optomed Plc ("Optomed" or the "Company") has received a notification in accordance with the Chapter 9, Section 5 of the Finnish Securities Markets Act (as amended, the "SMA") from Robert Bosch Venture Capital GmbH ("RBVC"). According to the notification, the total holdings in Optomed shares and votes held by RBVC has decreased to below 5.00 % per cent of all of the registered shares in Optomed on 25 May 2021.

The total number of the Company's registered shares amounts to 14,003,144 shares. Each share entitles to one vote.

The total position of RBVC subject to the notification:

% of % of shares and voting rights Total of
shares and through financial instruments (total both in %
voting of B) (A+B)
rights
(total
of A)
Resulting 3.45 % - 3.45 %
situation on the
date on
which threshold
was crossed or
reached
Position of 7.90 % - 7.90 %
previous
notification
(if applicable)

Notified details of the resulting situation on the date on which the threshold was crossed or reached:

A: Shares and voting rights

Class/type of Number % of shares and voting rights
sharesISIN of
code shares
and
voting
rights
Direct Indirect Direct Indirect
(SMA 9:5) (SMA 9:6 (SMA 9:5) (SMA 9:6 ja 9:7)
ja 9:7)
FI4000410881 482,473 - 3.45 % -
SUBTOTAL A 482,473 3.45 %

Information in relation to the person subject to the notification obligation as contained in the notification

The complete chain of controlled undertakings through which the shares, voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:

Name % of % of shares Total of both
shares and voting
and rights
voting through
rights financial
instruments
Robert Bosch 100 % - 100 % of Robert
Sechste Bosch Venture
Vermögensverwal Capital GmbH
-tungsgesellschaft
mbH
Robert Bosch GmbH 100 % - 100 % of Robert
Bosch Sechste
Vermögens
-verwaltungs
-gesell
-schaftmbH
Robert Bosch 93.99 % - 93.99 % of shares
Stiftung GmbH of of Robert Bosch
(charitable) shares, GmbH
no voting
rights
Robert Bosch 93.17 % 93.17 % of voting
Industrietreuhand of voting rights and 0.01%
KG rights, of shares of
(performs the 0.01% of Robert Bosch GmbH
entrepreneurial shares
ownership
functions)

Further enquiries

Sakari Knuutti, CLO, Optomed Plc, sakari.knuutti@optomed.com,+358(0)50 562 4077.

Optomed in Brief

Optomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras. Optomed combines handheld screening devices fundus cameras with software and artificial intelligence with the aim to transform the diagnostic process of blinding eye-diseases such as rapidly increasing diabetic retinopathy. In its business Optomed focuses on eye-screening devices and software solutions related R&D in Finland and sales through different channels in over 60 countries. The company has an extensive portfolio of 56 international patents protecting the technology.